AbbVie Inc. (ABBV) Financial Statements
AbbVie Inc. (ABBV) reported trailing twelve-month revenue of $64.4B (up 10.4% year on year) and net income of $6.3B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $18.2B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 504.8B
- P/E TTM
- 80.7
- Dividend yield
- 2.4%
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26. Results for the next quarter were released 5 Oct; these figures move once the 10-Q is filed.
| Line | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.79 | 19.96 | 22.86 | 25.64 | 28.22 | 32.75 | 33.27 | 45.80 | 56.20 | 58.05 | 54.32 | 56.33 | 61.16 | 64.39 | |
| Gross profit | 14.21 | 15.53 | 18.36 | 19.81 | 21.18 | 25.04 | 25.83 | 30.42 | 38.75 | 40.64 | 33.90 | 39.43 | 42.96 | 46.02 | |
| Research & development | 2.86 | 3.30 | 4.29 | 4.39 | 5.01 | 10.33 | 6.41 | 6.38 | 6.92 | 6.51 | 7.68 | 12.79 | 9.10 | 9.71 | |
| Operating income | 5.66 | 3.41 | 7.54 | 9.34 | 9.55 | 6.38 | 12.98 | 11.36 | 17.92 | 18.12 | 12.76 | 9.14 | 15.08 | 16.87 | |
| Pre-tax income | 5.33 | 2.37 | 6.65 | 7.88 | 7.73 | 5.20 | 8.43 | 3.40 | 12.99 | 13.48 | 6.25 | 3.72 | 6.60 | 8.70 | |
| Income tax | 1.20 | 0.60 | 1.50 | 1.93 | 2.42 | -0.49 | 0.54 | -1.22 | 1.44 | 1.63 | 1.38 | -0.57 | 2.36 | 2.38 | |
| Net income | 4.13 | 1.77 | 5.12 | 5.95 | 5.31 | 5.69 | 7.88 | 4.62 | 11.54 | 11.84 | 4.86 | 4.28 | 4.23 | 6.31 | |
| Diluted EPS ($) | 2.56 | 1.10 | 3.13 | 3.63 | 3.30 | 3.66 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 | 3.54 | |
| Diluted shares (bn) | 1.604 | 1.610 | 1.637 | 1.631 | 1.603 | 1.546 | 1.484 | 1.673 | 1.777 | 1.778 | 1.773 | 1.773 | 1.773 | — |
USD billions · SEC XBRL
AbbVie Inc. — questions
- What is AbbVie Inc.'s revenue?
- $64.4B over the twelve months to 2026-06-30, up 10.4% year on year, from its 10-Q and 10-K filings.
- What is AbbVie Inc.'s net income?
- $6.3B over the twelve months to 2026-06-30.
- What is AbbVie Inc.'s free cash flow?
- $18.2B over the twelve months to 2026-06-30.
- What are AbbVie Inc.'s diluted earnings per share?
- $3.54 over the twelve months to 2026-06-30.
Every figure on this page comes from AbbVie Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.